The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II pilot study of fosaprepitant (F) for the rescue of acute nausea and vomiting with moderately (MEC) or highly emetogenic chemotherapy (HEC) in adults.
Joseph S. Bubalo
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Ian D. Schnadig
No relevant relationships to disclose
Gabrielle Meyers
No relevant relationships to disclose
Andy I. Chen
No relevant relationships to disclose
Brandon M. Hayes-Lattin
No relevant relationships to disclose
Christopher W. Ryan
No relevant relationships to disclose
Jocelyn Digregorio
No relevant relationships to disclose
Richard T. Maziarz
No relevant relationships to disclose